



MEDIA CONTACT:

Kyla Thorpe, 954-397-3251

kthorpe@fscdr.org

Foundation For Sickle Cell Disease Research

March 21, 2014

FOR IMMEDIATE RELEASE:



**THE FOUNDATION FOR SICKLE CELL DISEASE
RESEARCH NAMES WILLIAM GANNON, MD AS
NEW CHAIRMAN TO ITS BOARD**

(Hollywood, FL.) The Foundation for Sickle Cell Disease Research has named William E. Gannon Jr., MD, MBA, as Chairman of its Board of Directors. The Foundation also named Zimbalist F. Chalk, MSM as Vice-Chairman. Under Dr. Gannon's leadership, The Foundation will finalize its overall structure and focus on fundraising efforts to support its various research and educational goals.

Dr. William Gannon serves as Chief Scientific Officer & Medical Director for Capital City Technical Consulting in Washington, DC. Prior to this, he served as Vice President for Clinical & Medical Affairs in the biotechnology arena. Dr. Gannon's experience includes managing clinical trials and operations as well as executing Phase I through Phase IV clinical trials in the United States, Europe and Asia. He received his M.B.A. in 1988, completing his medical training and clinical work at Ross University, Case Western Reserve and George Washington University.

Dr. Gannon joins the following members on the board: Lanetta Bronté Jordan, MD, MPH, MSPH, President and Chief Executive Officer; Betty Pace, MD, Chair of Research and Advisory Committee; Bacardi Jackson, Esq., Chair of Governance Committee Shelley-Ann Michelle Anderson, Director of Education; Ofelia Alvarez, MD, Chair of Sickle Cell Disease and Thalassemia (SCDT) Health Record; Latoya McCrea Anderson, Chair of Publication and Annette Lewis, MBA, CPA, Treasurer.

The Foundation for Sickle Disease Research (FSCDR) is a comprehensive, non-profit organization that provides a platform for researchers, healthcare providers, individuals and their families living with sickle cell disease and supporters to work collaboratively in identifying best practices that help in the management of sickle cell disease. FSCDR appreciates the benefits of being united in the common cause of sickle cell disease research and medical care with academia, pharmaceutical, biotechnology, and community organizations. For more information, visit fscdr.org.